Latest Ratios: P/E Ratio -11.9x · EV/EBITDA N/A · ROE -61.6%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.5B | $1.1B | $258M | $1.0B | $2.5B | — | — | — |
| Enterprise Value | $1.3B | $922M | $182M | $864M | $2.4B | — | — | — |
| P/E Ratio → | -11.88 | — | — | 21.03 | — | — | — | — |
| P/S Ratio | — | — | 2.95 | 2.71 | 110.55 | — | — | — |
| P/B Ratio | 5.63 | 3.74 | 1.56 | 2.38 | 7.22 | — | — | — |
| P/FCF | — | — | — | 96.49 | — | — | — | — |
| P/OCF | — | — | — | 86.44 | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 2.08 | 2.27 | 108.02 | — | — | — |
| EV / EBITDA | — | — | — | 21.67 | — | — | — | — |
| EV / EBIT | — | — | — | 22.27 | — | — | — | — |
| EV / FCF | — | — | — | 80.94 | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 51.8% | 93.3% | 86.5% | — | -3683.7% | -734.4% |
| Operating Margin | — | — | -360.2% | 10.2% | -905.7% | — | -6000.8% | -950.5% |
| Net Profit Margin | — | — | -345.4% | 12.9% | -892.4% | — | -6504.6% | -1039.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -61.6% | -61.6% | -100.9% | 12.7% | -209.4% | — | — | — |
| ROA | -55.0% | -55.0% | -84.9% | 10.8% | -79.8% | -146.9% | -488.1% | -460.1% |
| ROIC | -132.2% | -132.2% | -132.3% | 10.5% | -363.9% | — | — | — |
| ROCE | -64.5% | -64.5% | -104.8% | 9.9% | -93.0% | -174.1% | -1426.4% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.01 | 0.01 | 0.02 | — | — | — |
| Debt / EBITDA | — | — | — | 0.11 | — | — | — | — |
| Net Debt / Equity | — | -0.72 | -0.46 | -0.38 | -0.17 | — | — | — |
| Net Debt / EBITDA | — | — | — | -4.16 | — | — | — | — |
| Debt / FCF | — | — | — | -15.54 | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | -17.05 | -9.75 |
Net cash position: cash ($227M) exceeds total debt ($6M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 14.27 | 14.27 | 6.67 | 5.66 | 8.20 | 6.03 | 1.86 | 0.71 |
| Quick Ratio | 14.27 | 14.27 | 6.67 | 5.20 | 7.99 | 6.03 | 1.86 | 0.71 |
| Cash Ratio | 13.97 | 13.97 | 6.21 | 4.53 | 7.44 | 5.53 | 1.76 | 0.68 |
| Asset Turnover | — | — | 0.45 | 0.74 | 0.06 | — | 0.05 | 0.44 |
| Inventory Turnover | — | — | — | 0.66 | 0.31 | — | — | — |
| Days Sales Outstanding | — | — | 1.87 | 38.39 | 251.31 | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | 4.8% | — | — | — | — |
| FCF Yield | — | — | — | 1.0% | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $95M | $68M | $70M | $67M | $58M | $56M | $56M |
Clinical trial funding exhaustion
As reported in financial statements, Amylyx currently trades at a price-to-book ratio of 5.51, a figure that appears disconnected from its lack of revenue and suggests investors are pricing the firm based on residual cash rather than the speculative value of its remaining clinical-stage pipeline assets.
The negative P/E of -11.63 confirms the absence of earnings, rendering traditional valuation multiples largely irrelevant for assessing the company's intrinsic worth. Investors should monitor whether the current valuation floor holds as the cash balance continues to decline, as the market may eventually discount the company below its net cash position if clinical progress stalls.
Based on recent quarterly filings, the company's ROIC has deteriorated to -48.9% in 2026Q1, illustrating a sharp decline in capital efficiency as the firm shifts from a commercial entity to a clinical-stage organization with no revenue to generate returns on its invested capital base.
The consistent negative trend in ROE and ROIC suggests that the company is currently destroying shareholder value through its ongoing R&D expenditures. This trend warrants further investigation into whether the current clinical pipeline possesses the potential to eventually reverse these negative returns or if the capital allocation strategy remains fundamentally misaligned with long-term value creation.
According to the provided ratio data, the current ratio has expanded to 17.85 as of 2026Q1, which appears to indicate a strong liquidity position, yet this metric is misleading as it reflects the rapid depletion of liabilities rather than an improvement in the company's underlying operational health.
While the high current ratio suggests the firm can meet its short-term obligations, the lack of revenue means this liquidity is strictly finite and subject to continuous erosion. Investors should interpret this high ratio as a temporary defensive posture that will inevitably tighten as the company funds its multi-year clinical trials.
As indicated by the quarterly data, the current ratio is the most commonly misapplied metric for Amylyx, as it obscures the reality that the company's liquidity is not a sign of operational strength but rather a reflection of a shrinking balance sheet following the Relyvrio withdrawal.
Analysts should instead focus on the 'Cash Burn Rate' and 'Runway to Data Readout' as more accurate indicators of financial viability. Relying on the current ratio may lead to a false sense of security, as it fails to account for the lack of future cash inflows required to sustain the business beyond the current cash balance.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AMLX stock.
Amylyx Pharmaceuticals, Inc.'s current P/E ratio is -11.9x. The historical average is 21.0x.
Amylyx Pharmaceuticals, Inc.'s return on equity (ROE) is -61.6%. The historical average is -89.8%.
Based on historical data, Amylyx Pharmaceuticals, Inc. is trading at a P/E of -11.9x. Compare with industry peers and growth rates for a complete picture.